CUE-101 is under clinical development by Cue Biopharma and currently in Phase I for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CUE-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CUE-101 is under development for the treatment of human papillomavirus (HPV) associated cancers (head and neck cancer squamous cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, anal cancer, oropharyngeal squamous-cell carcinoma (OPSCC) and cervical cancer). The drug candidate is administered by parenteral route. Drug candidate consist of IL-2 and a pMHC composed of HLA-A 02:01 complexed with a dominant peptide derived from the human papilloma virus E7 protein (HPV-E7). CUE-101 is developed using Immuno-STAT technology. It was also under development for the treatment of non-small cell lung cancer. It is acts by targeting HPV-E7 (human papilloma virus- E7 oncoprotein) interleukin 2 receptor.
Cue Biopharma overview
Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse. CUE-200 series to give a boost to exhausted T cells and CUE-300 series. It offers therapy in areas of immuno onncology, infectious diseases and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to regulate the body’s intrinsic immune system. The company also provides clinical trails and research services. Cue Biopharma is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CUE-101’s drug-specific PTSR and LoA scores, buy the report here.